About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company’s approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococcus (VRE) and Penicillin-Resistant Streptococcus pneumoniae (PRSP). For more information, please visit: www.acurxpharma.com.
Methicillin-Resistant Staphylococcus aureus (MRSA)
Vancomycin-Resistant Enterococcus (VRE)
Penicillin-Resistant Streptococcus pneumoniae (PRSP)
David P. Luci, CPA, Esq. − Co-Founder and President and CEO
Robert J. DeLuccia − Co-Founder and Executive Chairman
Robert G. Shawah, CPA − Co-Founder & Chief Financial Officer